Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).

Abstract

INTRODUCTION:

Many Chinese patients who are uncontrolled by oral antidiabetic drugs (OADs) receive short-term intensive insulin therapy (IIT) in hospital to rapidly relieve glucose-associated toxicity and to preserve/improve β-cell function. However, evidence for optimizing insulin algorithms for maintenance treatment after IIT is lacking. This study will compare the efficacy and safety of basal insulin-based treatment versus twice-daily premixed insulin in type 2 diabetes mellitus (T2DM) patients after short-term in-hospital IIT.

METHODS:

This 26-week randomized, multicenter, positive-controlled, open-label, parallel-group study will enroll approximately 400 male and female patients aged 18-70 years with poorly-controlled T2DM (HbA1c > 7.5%) despite treatment with metformin plus at least one other OAD for 8 or more weeks. During a run-in period of 7-10 days, patients will be treated in-hospital with IIT comprising insulin glargine (Lantus®) once daily and insulin glulisine (Apidra®) three times daily; both regimens will be titrated daily to achieve the glycemic goal. Eligible patients will then be randomized in a 1:1 ratio to insulin glargine plus OADs or twice-daily premixed insulin (NovoLog® Mix 70/30) for 24 weeks, with metformin maintained throughout the study in both treatment groups. The primary endpoint is HbA1c change from baseline to week 24. Secondary endpoints include assessment of fasting plasma glucose, total daily insulin dose, hypoglycemia incidence, body weight change, adverse events, and patient satisfaction.

DISCUSSION:

Given the current lack of clinical data, this study will provide evidence supporting safe and effective glycemic control using basal insulin glargine-based therapy plus OADs compared with twice-daily premixed insulin in Chinese patients with T2DM after short-term IIT. This will assist physicians by providing a wider choice of treatments.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT03359837 (registered on 2 December 2017).

• Authors: Jing Liu, Xia Jiang, Binhua Xu, Guoping Wang, Nan Cui, Xia Zhang, Jingcheng Liu, Yiming Mu, Lixin Guo
• Journal: Advances in therapy (Adv Ther) Vol. 37 Issue 4 Pg. 1675-1687 (04 2020) ISSN: 1865-8652 [Electronic] United States
• PMID: 32130661 (Publication Type: Clinical Trial Protocol, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Insulin, Long-Acting
• insulin glulisine
• Metformin

Topics

• Adolescent
• Adult
• Aged
• Blood Glucose (drug effects)
• China
• Diabetes Mellitus, Type 2 (drug therapy)
• Drug Therapy, Combination
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemia (chemically induced)
• Hypoglycemic Agents (therapeutic use)
• Insulin (analogs & derivatives, therapeutic use)
• Insulin, Long-Acting (therapeutic use)
• Male
• Metformin (administration & dosage)
• Middle Aged
• Multicenter Studies as Topic
• Patient Satisfaction
• Randomized Controlled Trials as Topic
• Young Adult